Bioz Announces the Expansion of its Distinguished Advisory Board with Two Industry Leaders

PALO ALTO, Calif. - Dec. 20, 2018 (2:00 pm PT) --

Bioz Inc., a company that has developed the world’s first and most comprehensive A.I. search engine for scientific experimentation, today announced an expansion of its Advisory Board, with leaders from biopharma, life science tools, and procurement.

"The new Bioz Advisory Board members, accomplished leaders in their respective fields, share Bioz’ vision of advancing and improving life science experimentation through recommending products that will work best in experiments, based on mining and structuring objective data from within millions of published scientific research articles," said Dr. Karin Lachmi, co-founder and Chief Scientific Officer of Bioz.

"We’re proud to have Josef’s and Gamble’s many years of experience on our side," said Daniel Levitt, CEO, Bioz. "Our deep A.I. technology is transforming the life science research and biopharma R&D industries, and with the support of leaders from within the industry, we will be able ensure that every scientist and supplier benefits from a well-informed and highly efficient value chain."

"The new Advisory Board members have joined as strong believers in Bioz’ objective of bringing transparency and clarity to the process of selecting the optimal products for experimentation. The Advisory Board will advise Bioz as it continues to disrupt life science research and R&D, by guiding researchers in making faster and smarter decisions when performing experiments, ultimately speeding up drug discovery and increasing the rate of success in finding cures for diseases.The two new Bioz Advisory Board members are:

Josef Zihlmann, who served for over three decades in leading companies in the life science tool industry, most recently as the VP of MilliporeSigma (Merck), where he led a diverse range of functions, covering R&D, BD, M&A, procurement, compliance, sales, marketing, and the management of large product portfolios. Josef has a high affinity for science and cutting edge technology, and depth of insight into customer behavior.

"I’m proud to be part of Bioz’ Advisory Board and to work alongside such an esteemed and accomplished board who share the mission of advancing life science research by implementing modern technologies, ultimately leading to faster cure rates for diseases and improving lives," said Josef Zihlmann, former VP at MilliporeSigma (Merck), "I have been working in the life science space for over 30-years, and wish that Bioz’ technology would have been available earlier, as this technology guides scientists in the identification, selection, and procurement of the best reagents and tools, helping to move the entire industry forward."

Gamble Heffernan, who served in multiple executive roles, including GM of eBusiness at GE Healthcare, VP at Johnson & Johnson, VP at Cardinal Health, and SVP at SciQuest (JAGGAER). She has deep leadership experience in healthcare, SaaS solutions, predictive analytics, and AI/ML/NLP.

"I am thrilled to be joining the Advisory Board of Bioz. The impact that Bioz is having on the selection and procurement of products that scientists need for biopharma R&D, is revolutionary," says Gamble Heffernan. "Bioz technology, using advanced A.I. to drive better purchase decisions, is a game-changer for both the academic research and biopharma R&D industries, and I look forward to taking part in this disruptive mission."

Bioz’ technology helps researchers quickly select products, plan experiments, write papers, apply for grants and collaborate, ultimately speeding up experimentation and drug discovery. The software architecture taps the latest advances in Natural Language Processing (NLP) and Machine Learning (ML) to mine and structure hundreds of millions of pages of complex and unstructured scientific papers placing an unprecedented amount of summarized scientific experimentation knowledge at researchers’ fingertips.

Bioz Stars provides unbiased and objective algorithmic scores that are displayed for over 300 million life science products, tools, reagents, lab equipment, instruments, assays and kits. The technology is based on the analysis of 27 millions of peer-reviewed papers using a groundbreaking algorithm with weighted quantitative and qualitative parameters. The Bioz Stars are already started to become an industry standard as important tool for scientist to quickly and accurately choose their product based on pure data.